(Q79643291)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931979%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

title

Anticoagulant therapy during cardiopulmonary bypass (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931979%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931979%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

Richard C Becker

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931979%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

19 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931979%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thrombosis and Thrombolysis

24 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931979%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931979%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931979%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

218-228

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931979%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11239-008-0280-4

24 December 2019

exact match

0 references

cites work

Plasma-modified ACT can be used to monitor bivalirudin (Angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia

1 reference

12 December 2020

Current anticoagulant therapy--unmet clinical needs

1 reference

12 December 2020

Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass

1 reference

12 December 2020

Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery

1 reference

12 December 2020

Direct thrombin inhibitors for anticoagulation

1 reference

12 December 2020

Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)

1 reference

12 December 2020

Cardiopulmonary bypass for complex cardiac surgery using bivalirudin anticoagulation in a patient with heparin antibodies.

1 reference

12 December 2020

Factor IX is activated in vivo by the tissue factor mechanism

1 reference

12 December 2020

Heparinless cardiopulmonary bypass with ancrod

1 reference

12 December 2020

A novel anti-thrombotic heparinoid (ORG 10172) devoid of bleeding inducing capacity: A survey of its pharmacological properties in experimental animal models

1 reference

12 December 2020

Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting

1 reference

12 December 2020

Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass

1 reference

12 December 2020

Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis

1 reference

12 December 2020

Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation

1 reference

12 December 2020

First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity

1 reference

12 December 2020

Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial

1 reference

12 December 2020

Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons

1 reference

12 December 2020

Bivalirudin: pharmacology and clinical applications

1 reference

12 December 2020

Platelets and cardiopulmonary bypass

1 reference

12 December 2020

Anticoagulation management and cardiac surgery in patients with heparin-induced thrombocytopenia

1 reference

12 December 2020

Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation.

1 reference

12 December 2020

The mechanism of action of thrombin inhibitors

1 reference

12 December 2020

Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series

1 reference

12 December 2020

Case 1-2006: off-pump coronary artery bypass graft surgery anticoagulation with bivalirudin: a patient with heparin-induced thrombocytopenia syndrome type II and renal failure

1 reference

12 December 2020

Cardiac bypass haemostasis: putting blood through the mill

1 reference

12 December 2020

Thrombin during cardiopulmonary bypass

1 reference

12 December 2020

Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients

1 reference

12 December 2020

Heparin-induced thrombocytopenia and the use of r-hirudin during cardiopulmonary bypass.

1 reference

12 December 2020

Cardiopulmonary bypass in humans: bypassing unfractionated heparin

1 reference

12 December 2020

A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II : adaptation of the ecarin clotting time to the act II device

1 reference

12 December 2020

Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model

1 reference

12 December 2020

Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid

1 reference

12 December 2020

Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia [corrected].

1 reference

12 December 2020

Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

1 reference

12 December 2020

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

12 December 2020

Heparin, platelet aggregation, neutrophils, and cardiopulmonary bypass

1 reference

12 December 2020

Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial

1 reference

12 December 2020

Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery

1 reference

12 December 2020

Clinical pharmacology and drug safety: Lessons from hirudin*

1 reference

12 December 2020

r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons

1 reference

12 December 2020

Activation of coagulation and fibrinolysis during cardiothoracic operations

1 reference

12 December 2020

A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery

1 reference

12 December 2020

Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study

1 reference

12 December 2020

Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.

1 reference

12 December 2020

One month follow-up of haemostatic variables in patients undergoing aortocoronary bypass surgery. Effect of aprotinin

1 reference

12 December 2020

Fifty years of open-heart surgery

1 reference

12 December 2020

Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery

1 reference

12 December 2020

Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model

1 reference

12 December 2020

Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines

1 reference

12 December 2020

Antithrombotic therapy in cardiac surgery

1 reference

12 December 2020

An Assessment of Different Filter Systems for Extracorporeal Elimination of Bivalirudin: An In Vitro Study

1 reference

12 December 2020

A novel anti-tissue factor monoclonal antibody with anticoagulant potency derived from synthesized multiple antigenic peptide through blocking FX combination with TF.

1 reference

12 December 2020

Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation

1 reference

12 December 2020

Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems

1 reference

12 December 2020

Anticoagulation for patients with heparin-induced thrombocytopenia using recombinant hirudin during cardiopulmonary bypass

1 reference

12 December 2020

A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study

1 reference

12 December 2020

A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor

1 reference

12 December 2020

A new anticoagulant-antidote pair: control of thrombin activity by aptamers and porphyrins

1 reference

12 December 2020

Low molecular weight (LMW) heparin derivatives in experimental extra-corporeal circulation (ECC).

1 reference

12 December 2020

Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass

1 reference

12 December 2020

Recombinant hirudin enhances cardiac output and decreases systemic vascular resistance during reperfusion after cardiopulmonary bypass in a porcine model

1 reference

12 December 2020

A baboon model for hematologic studies of cardiopulmonary bypass

1 reference

12 December 2020

Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations

1 reference

12 December 2020

Use of bivalirudin as an anticoagulant during cardiopulmonary bypass.

1 reference

12 December 2020

Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery

1 reference

12 December 2020

Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass

1 reference

12 December 2020

Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation

1 reference

12 December 2020

Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting

1 reference

12 December 2020

Bleeding complications associated with cardiopulmonary bypass.

1 reference

12 December 2020

Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient

1 reference

12 December 2020

Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia

1 reference

12 December 2020

Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.

1 reference

12 December 2020

RNA aptamers as reversible antagonists of coagulation factor IXa.

1 reference

12 December 2020

Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor

1 reference

12 December 2020

Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).

1 reference

12 December 2020

Recombinant hirudin as an anticoagulant during cardiac operations: experiments in a pig model

1 reference

12 December 2020

Management of heparin resistance during cardiopulmonary bypass: The effect of five different anticoagulation strategies on hemostatic activation

1 reference

12 December 2020

Reliability of the heparin management test for monitoring high levels of unfractionated heparin: in vitro findings in volunteers versus in vivo findings during cardiopulmonary bypass

1 reference

12 December 2020

Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.

1 reference

12 December 2020

Heparin to pentasaccharide and beyond: the end is not in sight

1 reference

12 December 2020

Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172.

1 reference

12 December 2020

Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass

1 reference

12 December 2020

Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: results of a pilot study

1 reference

12 December 2020

Mechanisms of thrombin generation during surgery and cardiopulmonary bypass

1 reference

12 December 2020

"Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass

1 reference

12 December 2020

Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.

1 reference

12 December 2020

A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction

1 reference

12 December 2020

An ELISA for factor X activation peptide: application to the investigation of thrombogenesis in cardiopulmonary bypass

1 reference

12 December 2020

Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study

1 reference

12 December 2020

New anticoagulant agents: direct thrombin inhibitors

1 reference

12 December 2020

Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass

1 reference

12 December 2020

Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa.

1 reference

12 December 2020

Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).

1 reference

12 December 2020

Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model

1 reference

12 December 2020

Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin

1 reference

12 December 2020

Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass

1 reference

12 December 2020

Mechanisms and attenuation of hemostatic activation during extracorporeal circulation

1 reference

12 December 2020

Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia

1 reference

12 December 2020

Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin

1 reference

12 December 2020

Hirudin as anticoagulant for cardiopulmonary bypass: importance of preoperative renal function

1 reference

12 December 2020

Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the "EVOLUTION OFF" trial

1 reference

12 December 2020

Optimizing management of hirudin anticoagulation

1 reference

12 December 2020

The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations

1 reference

12 December 2020

Tifacogin, recombinant tissue factor pathway inhibitor.

1 reference

12 December 2020

Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model

1 reference

12 December 2020

Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass.

1 reference

12 December 2020

Heparin-associated thrombocytopenia: management of patients for open heart surgery. Case reports describing the use of iloprost.

1 reference

12 December 2020

Activation of coagulation and fibrinolysis during coronary surgery: on-pump versus off-pump techniques

1 reference

12 December 2020

10.1007/S11239-008-0280-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931979%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference